Digestive Diseases and Sciences

, Volume 45, Issue 1, pp 68–76

Effect of Pretreatment Antibiotic Resistance to Metronidazole and Clarithromycin on Outcome of Helicobacter pylori Therapy

  • Maria Pina Dore
  • Gioacchino Leandro
  • Giuseppe Realdi
  • Antonia Rogado Sepulveda
  • David Yates Graham
Article

Abstract

Our purpose was to define the effect of pretreatment Helicobacter pylori resistance to metronidazole or to clarithromycin on the success of antimicrobial therapy. We used 75 key words to perform a literature search in MEDLINE as well as manual searches to identify clinical treatment trials that provided results in relation to H. pylori susceptibility to metronidazole and clarithromycin or both during the period 1984–1997 (abstracts were not included). Meta-analysis was done with both fixed- and random-effect models; results were shown using Galbraith's radial plots. We identified 49 papers with 65 arms for metronidazole (3594 patients, 2434 harboring H. pylori strains sensitive to metronidazole and 1160 harboring resistant strains). Metronidazole resistance reduced effectiveness by an average of 37.7% (95% CI = 29.6–45.7%). The variability in the risk difference for metronidazole was 122.0 to −90.6 and the chi-square value for heterogeneity was significant (P < 0.001). Susceptibility tests for clarithromycin were performed in 12 studies (501 patients, 468 harboring H. pylori strains sensitive to clarithromycin and 33 harboring resistant strains). Clarithromycin resistance reduced effectiveness by an average of 55% (95% CI = 33–78%). We found no common factors that allowed patients to be divided into subgroups with additional factors significantly associated with resistance. In conclusion, metronidazole or clarithromycin pretreatment resistant H. pylori are the main factors responsible for treatment failure with regimens using these compounds. If H. pylori antibiotic resistance continues to increase, pretherapy antibiotic sensitivity testing might become necessary in many regions.

meta-analysis metronidazole clarithromycin resistance Helicobacter pylori therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Anonymous: Gastroenterologist in Sydney-histology and Helicobacter. Lancet 336:779-780, 1990Google Scholar
  2. 2.
    O'Riordan T, Mathai E, Tobin A, McKenna D, Keane C, Sweeney E, O'Morain C: Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 31:999-1002, 1990PubMedGoogle Scholar
  3. 3.
    Megraud F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 11 (suppl 1):43-53, 1997PubMedGoogle Scholar
  4. 4.
    Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496, 1992PubMedGoogle Scholar
  5. 5.
    Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L, Manca A, Are BM, Massarelli G, Mura I, Maida A, Graham DY: Pre-treatment antibiotic resistance in Helicobacter pylori infection: Results of three randomized, controlled studies. Helicobacter 4:106-112, 1999PubMedGoogle Scholar
  6. 6.
    Glupczynski Y, Burette A: Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am J Gastroenterol 85:1545-1551, 1990PubMedGoogle Scholar
  7. 7.
    Glupczynski Y: European Multicentre Study Group on antibiotic susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 11:777-781, 1992PubMedGoogle Scholar
  8. 8.
    Haas CE, Nix DE, Shentag JJ: In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 34:1637-1641, 1990PubMedGoogle Scholar
  9. 9.
    Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourne S, Phillips M: Prevention of nitroimidazole resistance in Campylobacter pyloridis by coadministration of colloidal bismuth subcitrate: Clinical and in vitro studies. J Clin Pathol 41:207-210, 1988PubMedGoogle Scholar
  10. 10.
    Graham DY, Dore MP: Variability in the outcome of treatment of Helicobacter pylori infection: A critical analysis. In Helicobacter pylori Basic Mechanisms to Clinical Cure 1998. RH Hunt and GNJ Tytgat (eds). Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998, pp 426-441Google Scholar
  11. 11.
    Graham DY: Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology 115:1272-1277, 1998PubMedGoogle Scholar
  12. 12.
    Graham DY, de Boer WA, Tytgat GN: Choosing the best anti-Helicobacter pylori therapy: Effect of antimicrobial resistance. Am J Gastroenterol 91:1072-1076, 1996PubMedGoogle Scholar
  13. 13.
    Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889-894, 1988PubMedGoogle Scholar
  14. 14.
    META: The Right Handbook and Software to Understand and Practice Meta-Analysis. G. Leandro (eds). www.Media.it/META (in progress)Google Scholar
  15. 15.
    Xia H, Keane CT, Beattie S, O'Morain CA: Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 38:2357-2361, 1994PubMedGoogle Scholar
  16. 16.
    Rautelin H, Seppala K, Renkonen OV, Vainio U, Kosunen TU: Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 36:163-166, 1992PubMedGoogle Scholar
  17. 17.
    Lerang F, Moum B, Haug JB, Tolas P, Breder O, Aubert E, Hoie O, Soberg T, Flaaten B, Farup P, Berge T: Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: Does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 92:248-253, 1997PubMedGoogle Scholar
  18. 18.
    Fraser AG, Moore L, Ali MR, Chua LE, Hollis B, Little SV: An audit of low dose triple therapy for eradication of Helicobacter pylori: NZ Med J 109:290-292, 1996Google Scholar
  19. 19.
    Ching CK, Leung KP, Yung RW, Lam SK, Wong BC, Lai KC: Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 38:675-678, 1996PubMedGoogle Scholar
  20. 20.
    Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Kolkman JJ, Vandenbroucke-Grauls CM: Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 142:37-42, 1996PubMedGoogle Scholar
  21. 21.
    de Boer WA, van Etten RJ, Schade RW, Ouwehand ME, Schneeberger PM, van Unnik AJ, Tytgat GN: One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 11:109-112, 1997Google Scholar
  22. 22.
    Thijs JC, Van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A: One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: The significance of imidazole resistance. Aliment Pharmacol Ther 11:305-309, 1997PubMedGoogle Scholar
  23. 23.
    Yousfi MM, el-Zimaity HM, al-Assi MT, Cole RA, Genta RM, Graham DY: Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 9:209-212, 1995PubMedGoogle Scholar
  24. 24.
    Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, Purser K, Harrison G, Brown C, Gant PW, Jones PH, Trowell JE: Helicobacter pylori eradication: Efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 86:743-750, 1993PubMedGoogle Scholar
  25. 25.
    Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 9:41-46, 1995Google Scholar
  26. 26.
    Seppala K, Farkkila M, Nuutinen H, Hakala K, Vaananen H, Rautelin H, Kosunen TU: Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol 27:973-976, 1992PubMedGoogle Scholar
  27. 27.
    Thijs JC, Van Zwet AA, Oey HB: Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 28:934-938, 1993PubMedGoogle Scholar
  28. 28.
    Hosking SW, Ling TK, Chung SC, Yung MY, Cheng AF, Sung JJ, Li AK: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: Randomized controlled trial. Lancet 343:508-510, 1994CrossRefPubMedGoogle Scholar
  29. 29.
    de Boer WA, Driessen WM, Jansz AR, Tytgat GN: Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: Results of a randomized prospective single-center study. Eur J Gastroenterol Hepatol 7:1189-1194, 1995PubMedGoogle Scholar
  30. 30.
    de Boer WA, Driessen W, Jansz A, Tytgat GN: Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345:817-820, 1995CrossRefPubMedGoogle Scholar
  31. 31.
    Noach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GN: Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 26:321-327, 1994PubMedGoogle Scholar
  32. 32.
    Lynch DA, Sobala GM, Gallacher B, Dixon MF, Axon AT: Effectiveness of a five times daily triple therapy regimen against Helicobacter pylori. J Antimicrob Chemother 33:877-879, 1994PubMedGoogle Scholar
  33. 33.
    Labenz J, Peitz U, Tillenburg B, Becker T, Borsch G, Stolte M: Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori. Leber Magen Darm 25:122-127, 1995PubMedGoogle Scholar
  34. 34.
    Logan RP, Gummett PA, Schaufelberger HD, Greaves RR, Mendelson GM, Walker MM, Thomas PH, Baron JH, Misiewicz JJ: Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 35:323-326, 1994PubMedGoogle Scholar
  35. 35.
    Wyeth JW, Pounder RE, Duggan AE, O'Morain CA, Schaufelberger HD, De Koster EH, Rauws EA, Bardhan KD, Gilvarry J, Buckley MJ, Gummett PA, Logan RP: The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 10:623-630, 1996PubMedGoogle Scholar
  36. 36.
    Hentschel E, Brandstatter G, Dragosics B, Hirschl AM, Nemec H, Schutze K, Taufer M, Wurzer H: Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 328:308-312, 1993PubMedGoogle Scholar
  37. 37.
    Moayyedi P, Sahay P, Tompkins DS, Axon AT: Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol 7:835-840, 1995Google Scholar
  38. 38.
    Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel Huinink J: Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: A multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 91:93-97, 1996PubMedGoogle Scholar
  39. 39.
    Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE. Experience with "triple" anti-Helicobacter pylori eradication therapy: Side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6:427-435, 1992PubMedGoogle Scholar
  40. 40.
    Logan RP, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH: One week eradication regimen for Helicobacter pylori. Lancet 338:1249-1252, 1991PubMedGoogle Scholar
  41. 41.
    Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drnec J, Prokocimer P, Siepman N: Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. Am J Gastroenterol 88:1860-1864, 1993PubMedGoogle Scholar
  42. 42.
    de Boer WA, Driessen WM, Tytgat GN: Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 9:633-638, 1995PubMedGoogle Scholar
  43. 43.
    Gotoh A, Kawakami Y, Akahane T, Akamatsu T, Shimizu T, Kiyosawa K, Katsuyama T: Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Microbiol Immunol 41:7-12, 1997PubMedGoogle Scholar
  44. 44.
    Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H: Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37:477-481, 1995PubMedGoogle Scholar
  45. 45.
    de Boer WA, van Etten RJ, Schade RW, Ouwehand ME, Schneeberger PM, Tytgat GN: 4-Day lansoprazole quadruple therapy: A highly effective cure for Helicobacter pylori infection. Am J Gastroenterol 91:1778-1782, 1996PubMedGoogle Scholar
  46. 46.
    Gisbert JP, Boixeda D, de Rafael L, Martin de Argila C, Bermejo F, Garcia Plaza A: The effect of "triple therapy" on the eradicating of H. pylori and the healing of a duodenal ulcer. The initial study and 6 months later. Rev Esp Enferm Dig 87:193-198, 1995PubMedGoogle Scholar
  47. 47.
    Schütze K, Hentschel E, Hirschl AM: Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia. Eur J Gastroenterol Hepatol 8:41-46, 1996PubMedGoogle Scholar
  48. 48.
    Glupczynski Y, Burette A, De Koster E, Nyst JF, Deltenre M, Cadranel S, Bourdeaux L, De Vos D: Metronidazole resistance in Helicobacter pylori. Lancet 335:976-977, 1990Google Scholar
  49. 49.
    Bell GD, Powell KU: Helicobacter pylori reinfection after apparent eradication-the Ipswich experience. Scand J Gastroenterol 215(suppl 31):96-104, 1996Google Scholar
  50. 50.
    DeCross AJ, Marshall BJ, McCallum RW, Hoffman SR, Barrett LJ, Guerrant RL: Metronidazole susceptibility testing for Helicobacter pylori: Comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 31:1971-1974, 1993PubMedGoogle Scholar
  51. 51.
    Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, Jones PH, Trowell JE: Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Ther 4:651-657, 1990PubMedGoogle Scholar
  52. 52.
    Glupczynski Y, Burette A: Eradicating Helicobacter pylori. Lancet 339:54-55, 1992Google Scholar
  53. 53.
    Gisbert JP, Boixeda D, de Rafael L, Redondo C, Martin de Argila C, Bermejo F: Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori. Rev Esp Enferm Dig 88:317-322, 1996PubMedGoogle Scholar
  54. 54.
    Midolo PD, Lambert JR, Turnidge J: Metronidazole resistance: A predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 11:290-292, 1996PubMedGoogle Scholar
  55. 55.
    Xia H, Daw MA, Sant S, Beattie S, Keane CT, O'Morain CA: Clinical efficacy of triple therapy in Helicobacter pyloriassociated duodenal ulcer. Eur J Gastroenterol Hepatol 5:141-144, 1993Google Scholar
  56. 56.
    Harris AW, Pryce DI, Gabe SM, Karim QN, Walker MM, Langworthy H, Baron JH, Misiewicz JJ: Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 10:1005-1008, 1996PubMedGoogle Scholar
  57. 57.
    Powell KU, Bell GD, Boweden AF, Trowell JE, Jones PH: Helicobacter pylori eradication therapy: A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole. Br J Clin Res 6:163-169, 1995Google Scholar
  58. 58.
    Moayyedi P, Langworthy H, Shanahan K, Tompkins DS, Dixon MF, Chalmers DM, Axon AT: Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter 1:71-74, 1996PubMedGoogle Scholar
  59. 59.
    Schwartz H, Krause R, Siepman N, Haber M, Weissfeld A, Kidd S, Rose P, Sahba B: Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: A short report. Helicobacter 1:251-255, 1996PubMedGoogle Scholar
  60. 60.
    Tompkins DS, Perkin J, Smith C: Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 2:185-187, 1997PubMedGoogle Scholar
  61. 61.
    Tucci A, Corinaldesi R, Stanghellini V, Paparo GF, Gasperoni S, Biasco G, Varoli O, Ricci-Maccarini M, Barbara L: One-day therapy for treatment of Helicobacter pylori infection. Dig Dis Sci 38:1670-1673, 1993PubMedGoogle Scholar
  62. 62.
    Thijs JC, Van Zwet AA, Moolenaar W, Oom JA, De Korte H, Runhaar: Short report: Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 8:131-134, 1994PubMedGoogle Scholar
  63. 63.
    Stupnicki T, Taufer M, Denk H, Ratschek M, Spath P, Graf K: Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Aliment Pharmacol Ther 10:193-197, 1996PubMedGoogle Scholar
  64. 64.
    Logan RP, Bardhan KD, Celestin LR, Theodossi A, Palmer KR, Reed PI, Baron JH, Misiewicz JJ: Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: A randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 9:417-442, 1995PubMedGoogle Scholar
  65. 65.
    van der Hulst RWM, Weel JF, van der Ende A, ten Kate FJ, Dankert J, Tytgat GN: Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 91:2333-2337, 1996PubMedGoogle Scholar
  66. 66.
    Lerang F, Moum B, Ragnhildstveit E, Haug JB, Hauge T, Tolas P, Aubert E, Henriksen M, Efskind PS, Nicolaysen K, Soberg T, Odegaard A, Berge T: A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: A prospective randomized 1-yr follow-up study. Am J Gastroenterol 92:653-658, 1997PubMedGoogle Scholar
  67. 67.
    Vautier G, Scott BB: A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther 11:107-108, 1997PubMedGoogle Scholar
  68. 68.
    Breuer T, Kim JG, Gurer IE, Graham DP, Osato M, Genta RM, Graham DY: Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 11:523-527, 1997PubMedGoogle Scholar
  69. 69.
    Witteman EM, Hopman WP, Becx MC, De Koning RW, Tytgat GN, Janssen AJ, Jansen JB: Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis. Aliment Pharmacol Ther 7:683-687, 1993PubMedGoogle Scholar
  70. 70.
    Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY: Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40:283-286, 1997PubMedGoogle Scholar
  71. 71.
    Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, Zulawinski L, Tanaka SK: Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1:227-228, 1996PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Maria Pina Dore
    • 1
    • 2
    • 3
  • Gioacchino Leandro
    • 1
    • 2
    • 3
  • Giuseppe Realdi
    • 1
    • 2
    • 3
  • Antonia Rogado Sepulveda
    • 1
    • 2
    • 3
  • David Yates Graham
    • 1
    • 2
    • 3
  1. 1.VA Medical Center and Baylor College of MedicineHouston
  2. 2.Department of Internal MedicineUniversity of SassariSassariItaly
  3. 3.IRCCS “S. De Bellis,” Castellana GrotteBariItaly

Personalised recommendations